Stay updated on Nivolumab vs. Everolimus in RCC: Clinical Trial

Sign up to get notified when there's something new on the Nivolumab vs. Everolimus in RCC: Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab vs. Everolimus in RCC: Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    Added Revision: v3.4.2 and removed the Notice about lapse in government funding and the previous Revision: v3.4.1.
    Difference
    0.2%
    Check dated 2026-02-11T11:48:11.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    Added a government funding lapse notice affecting site operations and a Lancet Oncology CheckMate 025 reference; removed the Lancet Oncology Erratum citation for that article (revision: v3.4.0).
    Difference
    0.2%
    Check dated 2026-02-04T10:30:04.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    The page now includes a 'Show glossary' toggle. Metadata labels were tweaked for capitalization ('Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data'), and the revision has been updated to v3.4.0.
    Difference
    0.1%
    Check dated 2026-01-28T06:19:22.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    Revision metadata updated from v3.3.3 to v3.3.4; this is a minor administrative update with no impact on study data or user-facing content. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-01-14T02:07:52.000Z thumbnail image
  6. Check
    49 days ago
    Change Detected
    Summary
    The Publications section now shows the CheckMate 025 quality‑of‑life article with an Erratum, replacing the previous non-Erratum citation.
    Difference
    0.0%
    Check dated 2026-01-06T23:13:17.000Z thumbnail image
  7. Check
    63 days ago
    Change Detected
    Summary
    Added a comprehensive list of Locations covering the United States, Canada, Australia, and Europe; removed the prior location blocks and the HHS Vulnerability Disclosure entry.
    Difference
    2%
    Check dated 2025-12-23T17:22:49.000Z thumbnail image

Stay in the know with updates to Nivolumab vs. Everolimus in RCC: Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab vs. Everolimus in RCC: Clinical Trial page.